CEPI to in­vest up to $80M on ChA­dOx vac­cine plat­form, pre­vi­ous­ly used in As­traZeneca/Ox­ford Covid jab

The Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions (CEPI) is al­lo­cat­ing up to $80 mil­lion for the Uni­ver­si­ty of Ox­ford to de­vel­op vac­cine pro­to­types, in­clud­ing ones based on its ChA­dOx ade­n­ovirus vec­tor plat­form, to com­bat dis­eases with out­break po­ten­tial. ChA­dOx is the same plat­form used by the uni­ver­si­ty and As­traZeneca to de­vel­op their Covid vac­cine Vaxzevria.

Pro­to­type ChA­dOx vac­cines will tar­get a range of high-risk vi­ral fam­i­lies, de­signed to be mod­i­fied if a new “Dis­ease X” is de­tect­ed that can lead to an out­break. The vac­cines will ad­vance through pre­clin­i­cal and ear­ly clin­i­cal test­ing, and will be­come a part of the knowl­edge and da­ta re­source Glob­al Vac­cine Li­brary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.